Habib Yaribeygi*, Mina Maleki, Fatemeh Nasimi, Tannaz Jamialahmadi, Fatima C. Stanford and Amirhossein Sahebkar* Pages 4256 - 4265 ( 10 )
The epicardial adipose tissue, which is referred to as fats surrounding the myocardium, is an active organ able to induce cardiovascular problems in pathophysiologic conditions through several pathways, such as inflammation, fibrosis, fat infiltration, and electrophysiologic problems. So, control of its volume and thickness, especially in patients with diabetes, is highly important. Incretin-based pharmacologic agents are newly developed antidiabetics that could provide further cardiovascular benefits through control and modulating epicardial adiposity. They can reduce cardiovascular risks by rapidly reducing epicardial adipose tissues, improving cardiac efficiency. We are at the first steps of a long way, but current evidence demonstrates the sum of possible mechanisms. In this study, we evaluate epicardial adiposity in physiologic and pathologic states and the impact of incretin-based drugs.
Diabetes mellitus, glucagon-like peptide-1, dipeptidyl peptidase-4 inhibitor, epicardial adiposity, heart failure, epicardial adipose tissue.